Business & Economy · 43 views
OKYO Pharma appoints Leerink Partners as sales agent for ATM equity offering
OKYO Pharma Ltd (NASDAQ:OKYO) a clinical-stage biopharmaceutical company focused on therapies for neuropathic corneal pain and inflammatory eye diseases, announced that it has transitioned its At-The-Market (ATM) equity offering facility…
Summary
OKYO Pharma Ltd (NASDAQ:OKYO) a clinical-stage biopharmaceutical company focused on therapies for neuropathic corneal pain and inflammatory eye diseases, announced that it has transitioned its At-The-Market (ATM) equity offering facility to Leerink Partners. Leerink Partners will replace B. Riley Securities as the exclusive sales agent for the program, which allows the company to sell common shares directly into the market at prevailing prices, subject to market conditions and company discretion.
AI summaries can be wrong sometimes—always verify important details using the source article.
How AI & Automation are usedCoverage Context
More from Business & Economy
Continue reading recent Business & Economy coverage
- Stocks rise to kick off October as AI-related names gain: Live updatesContinue reading
- The stock market is a hollow tree that could be about to snap, warns bond king GundlachContinue reading
- U.S. Bond Yields Hit Highest Level Since 2002Continue reading
- HPE’s $1.2 billion order from Vultr puts its AI networking strategy to the testContinue reading
Support HappeningNow
Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.
Support HappeningNow